ClinicalTrials.gg
Not yet recruitingNCT06283628LMB-RFAUpdated Nov 2, 2026

Comparative Effectiveness of Two Different Approaches to Radiofrequency Ablation of Lumbar Medial Branch Nerves

An interventional study of Radiofrequency ablation of lumbar medial branch nerves. in Lumbar Spondylosis, sponsored by Milton S. Hershey Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 63 studies in Spondylosis with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Spondylosis · United States.

Planned enrollment
34th of 45
25 · median 45
Started
2027
the only one that year
No phase
34 of 63
8 open now
Primary completion
2028-12
later than 17 of 17 live
Registered
54th of 63
by date

Among the 63 studies in Spondylosis with a site in United States, this one is the 34th largest by planned enrollment of the 45 interventional ones that give a count, is the only one that started in 2027, is one of 34 with no phase, reaches primary completion later than 17 of the 17 other live ones, and was the 54th registered.

Spondylosis

142 studies on the registry are indexed under Spondylosis; 41 are open to participants now.

Browse Spondylosis studies →

Open to participants now

17 of the 63 studies in Spondylosis with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Spondylosis studies recruiting now, 12 (44%) set no upper age limit and 10 (37%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Spondylosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this voluntary research study is to determine whether the parasagittal approach to lumbar medial branch (LMB) nerve radio frequency ablation (RFA) will have greater efficacy than the traditional approach to lumbar medial branch nerve radio frequency ablation.

Read the detailed description

To determine whether the parasagittal approach to lumbar medial branch (LMB) nerve radiofrequency ablation (RFA) will have greater efficacy than the traditional approach to lumbar medial branch nerve radiofrequency ablation.

This will be accomplished by comparing the results between the newly proposed parasagittal approach and the traditional approach of medial branch RFA done on the same patient (different sites) with bilateral low back pain (LBP).

Traditional approach:

The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament (MAL) that may be ossified in up to 10% of the normal spine and, in such cases, potentially prevent proper coagulation of the medial branch nerve during the RFA procedure.

Parasagittal (new) approach:

Recently, Tran et al. showed that MAL is located more dorsally than it was thought earlier and, therefore, can't interfere with nerve coagulation during the RFA. Consequently, they proposed abandoning the 20-degree angle used for the traditional approach and placing the radiofrequency cannula parasagittally and more dorsally. It is proposed that, in order to achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.

03

Conditions studied

  • Lumbar Spondylosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Bilateral equally intense axial low back pain
  2. Pain duration of ≥ 6 months
  3. Three-day average NRS scores of ≥ 3/10
  4. Age greater than 18 years
  5. Failure of conservative treatment, including nonsteroidal anti-inflammatory medications and physical therapy
  6. Positive response to a series of two bilateral diagnostic lumbar medial branch nerve blocks (≥ 80% pain relief). This is the current standard of care.

Exclusion criteria

Exclusion Criteria:

  1. Radicular pain below the knee
  2. Systemic infection or localized infection at the anticipated introducer entry site
  3. Pregnancy
  4. Allergy to Lidocaine
  5. Bleeding dyscrasias
  6. Patients unable to give
  7. History of lumbar spine surgery at the affected levels
  8. History of previous bilateral lumbar RFA of medial branches within the past six months.
  9. Significant comorbid somatization or widespread pain with central sensitization
  10. Secondary gain identified due to ongoing legal proceedings or worker's compensation
  11. Cognitive impairment
  12. Any pre-existing condition at the discretion of the provider that may confound interpretation of results -
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Active comparator
    Subjects with traditional approach on the right side and parasagittal approach on the left side.

    Patients will undergo bilateral RFA; the right side will be done following the traditional approach, and the left side will be done following the parasagittal approach. Traditional approach is done by placing the electrode at a 20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process and transverse process of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament that may be ossified in up to 10% of the normal spine and potentially prevent proper coagulation of the medial branch nerve during the RFA procedure. Parasagittal (new) approach: is performed by placing the RF cannula parasagittally and more dorsally. To achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.

    Procedure: Radiofrequency ablation of lumbar medial branch nerves.

  • Active comparator
    Subjects with traditional approach on the left side and parasagittal approach on the right side.

    Patients will undergo bilateral RFA; the left side will be done following the traditional approach, and the right side will be done following the parasagittal approach. Traditional approach is done by placing the electrode at a 20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process and transverse process of the vertebral body to target the traversing medial branch nerve. The reason for the proposed angle is to avoid the mamillo-accessory ligament that may be ossified in up to 10% of the normal spine and potentially prevent proper coagulation of the medial branch nerve during the RFA procedure. Parasagittal (new) approach: is performed by placing the RF cannula parasagittally and more dorsally. To achieve maximum nerve coagulation, the electrode should be placed as parallel to the nerve as possible, and placing it parasagittally helps achieve this goal. The remainder of the procedure does not differ from the traditional method.

    Procedure: Radiofrequency ablation of lumbar medial branch nerves.

Interventions

  • ProcedureRadiofrequency ablation of lumbar medial branch nerves.

    Traditional approach: The electrode is introduced at a 15-20 degrees' ipsilateral oblique angle to the sagittal plane toward the junction of the superior articular process (SAP) and transverse process (TP) of the vertebral body to target the traversing medial branch nerve. Parasagittal (new) approach: The RF cannula is placed parasagittally and more dorsally. The remainder of the procedure does not differ from the traditional method.

06

What researchers measure

Primary outcomes

  1. The number of patients whose procedure was successful (gained 50% or more reduction in numeric rating pain (NRS) scores).

    The patients will describe the pain intensity using NRS - 11-point numeric rating scale, with 0 means no pain, and 10 - the worst possible pain intensity.

    Time frame: Baseline

  2. The number of patients whose procedure was successful (gained 50% or more reduction in numeric rating pain (NRS) scores).

    The patients will describe the pain intensity using NRS - 11-point numeric rating scale, with 0 means no pain, and 10 - the worst possible pain intensity.

    Time frame: 1 month post-procedure.

  3. The number of patients whose procedure was successful (gained 50% or more reduction in numeric rating pain (NRS) scores).

    The patients will describe the pain intensity using NRS - 11-point numeric rating scale, with 0 means no pain, and 10 - the worst possible pain intensity.

    Time frame: 6 months post-procedure.

Secondary outcomes

  1. Oswestry Disability index (ODI)

    10 questions assessing the functional impairment by the pain, using a 50 point scale, with 0 meaning no disability, and 50 meaning complete disability.

    Time frame: Baseline

  2. Oswestry Disability index (ODI)

    10 questions assessing the functional impairment by the pain, using a 50 point scale, with 0 meaning no disability, and 50 meaning complete disability.

    Time frame: 1 month post-procedure.

  3. Oswestry Disability index (ODI)

    10 questions assessing the functional impairment by the pain, using a 50 point scale, with 0 meaning no disability, and 50 meaning complete disability.

    Time frame: 6 months post-procedure.

Other outcomes

  1. Number of subjects who ceased requiring analgesia

    The patients will self-report their analgesic consumption.

    Time frame: Baseline

  2. Number of subjects who ceased requiring analgesia

    The patients will self-report their analgesic consumption.

    Time frame: 1 month post-procedure

  3. Number of subjects who ceased requiring analgesia

    The patients will self-report their analgesic consumption.

    Time frame: 6 months post-procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — IPD data that underlie the results reported in this article, after deidentification (text, tables, figures)

Supporting information: Study protocol

Time frame: Beginning 1 month and ending 3 years following article publication.

Access criteria: Researches who provide a methodologically sound proposal to achieve aims in the approved proposal. proposals should be directed to yvorobeychik@pennstatehealth.psu.edu.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2027; primary completion for Dec 2028, 16 months later.

Of 53 non-industry interventional studies with no phase under Spondylosis, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 42. This study's planned 16 months is above that.

Counting every sponsor, half of 58 studies reached it within 24 months; a quarter within 6 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2026 → Aug 2027, primary completion Dec 2026 → Dec 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Feb 28, 2024
StartEst.
Aug 2027was Aug 2026
Primary completionEst.
Dec 30, 2028was Dec 2026
CompletionEst.
Dec 30, 2028was Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Aug 2027
Nov 2, 2026
Primary completion
Dec 30, 2026→Dec 30, 2028
Nov 2, 2026
Study completion
Dec 30, 2026→Dec 30, 2028
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Aug 2026→Aug 2027
    Primary completion Dec 30, 2026→Dec 30, 2028
    Study completion Dec 30, 2026→Dec 30, 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06283628
Responsible party
Bunty Shah (Associate Professor, Department of Anesthesiology and Perioperative Medicine, Milton S. Hershey Medical Center) — Principal investigator
First posted
Feb 28, 2024
Start date
Aug 2027 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Nancy Ruth Jarbadan, BS
Contact
njarbadan@pennstatehealth.psu.edu
717-531-6135
Yakov Vorobeychik, MD PhD
principal investigator · Professor, Department of Anesthesiology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion